Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,036
  • Shares Outstanding, K 33,151
  • Annual Sales, $ 10,430 K
  • Annual Income, $ -32,580 K
  • 60-Month Beta 2.24
  • Price/Sales 5.28
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.31 +24.73%
on 06/12/19
1.71 -4.68%
on 06/24/19
+0.15 (+10.14%)
since 05/24/19
3-Month
1.31 +24.73%
on 06/12/19
2.65 -38.49%
on 03/25/19
+0.20 (+13.99%)
since 03/22/19
52-Week
0.60 +171.67%
on 12/11/18
2.65 -38.49%
on 03/25/19
-0.45 (-21.63%)
since 06/22/18

Most Recent Stories

More News
Curis: 1Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $9.9 million in its first quarter.

CRIS : 1.67 (+2.45%)
Curis Reports First Quarter 2019 Financial Results

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March...

CRIS : 1.67 (+2.45%)
Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter financial...

CRIS : 1.67 (+2.45%)
Curis Completes Mesothelioma Enrollment in CA-170 Study

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached its target...

CRIS : 1.67 (+2.45%)
Healthcare Companies Search for New Ways to Oppose the Spread of Cancer

Cancer is among one of the leading causes of death in the world since many countries are burdened by the lack of access to adequate healthcare, which results in the high number of deaths. In 2018, the...

CRIS : 1.67 (+2.45%)
CVM : 8.64 (+7.60%)
GERN : 1.52 (+2.70%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
NLNK : 1.54 (-1.91%)
Research Report Identifies Denison Mine, Obsidian Energy, Cherry Hill Mortgage Investment, Curis, DASAN Zhone Solutions, and CVD Equipment with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Denison Mine Corp (NYSE:DNN), Obsidian...

CVV : 3.63 (-2.68%)
OBE : 1.14 (-0.87%)
DNN : 0.53 (-1.85%)
CRIS : 1.67 (+2.45%)
DZSI : 12.72 (+0.16%)
CHMI : 16.33 (+0.18%)
Curis Regains Compliance with Nasdaq Continued Listing Requirements

Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from the Listing...

CRIS : 1.67 (+2.45%)
Curis Announces Advancement to the 200mg BID Cohort in the CA-4948 Study

Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it has begun dosing patients in the 5th cohort...

CRIS : 1.67 (+2.45%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 2, 2019, the independent Compensation...

CRIS : 1.67 (+2.45%)
Curis: 4Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $5.9 million in its fourth quarter.

CRIS : 1.67 (+2.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CRIS with:

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

2nd Resistance Point 1.75
1st Resistance Point 1.69
Last Price 1.67
1st Support Level 1.57
2nd Support Level 1.51

See More

52-Week High 2.65
Fibonacci 61.8% 1.87
Last Price 1.67
Fibonacci 50% 1.63
Fibonacci 38.2% 1.38
52-Week Low 0.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar